LBT's relative value believe it or not

Why I still believe LBT is highly undervalued relative to peers, namely RAP, NAN, IPD and AHZ.

LBT, revenue $8m to be fair still negligible just like everyone else being used for comparison below. Shares outstanding, unlike peers, LBT has only 115 million shares and mcap is only $74m at current SP of 64 cents. More importantly, LBT has FDA approved product with market worth billions. LBT recently has FDA approval for APAS with addressable market worth in billions, already in partnership with BM which commands a 30% market share, and APAS target market is not confined to BM's captured market but APAS can be adopted by competitors to significantly reduce their lab costs by as much as 40%. LBT is expected to announce LOI with global player soon as per Sep 2016 investor presentation. Woundvue also progressing.

Peers comparison:

RAP, revenue zilch, profit zilch, FDA approval zilch, mcap 280m, Now relative to market cap, If LBT has the same number of shares as RAP, LBT would still be at 9 cents, compared to RAP already trading at 47 cents.

NAN, revenue 42m, profit paltry 120 thousand, mcap $914m, yes close to $1 billion, Now relative to market cap, If LBT has the same number of shares as NAN, LBT would be at 25 cents, compared to NAN already trading at $3

IPD, revenue and profit info, none, probably none, mcap $600m, Now relative to market cap, If LBT has the same number of shares as IPD, LBT would only be at 20 cents, compared to IPD already trading at $1.70.

AHZ revenue $14m, at 28m Loss mcap $98m, FDA approved vascucel only has $500m global addressable market, Now relative to market cap, If LBT has the same number of shares as AHZ, LBT would only be at 18 cents, compared to AHZ already trading at 39 cents.

Please DYOR as usual, including what you think is the addressable market or potential and the stage of commercialisation. The info here are based on what I can quickly gather from LBT financials and investor presentation materials and some quick calcs of relative LBT current price if LBT had the same number of shares of peers. The unbelievably tight register of LBT I believe will make a huge difference in the near future when people realise it. Don't treat this as advice. Numbers are rounded for simplicity but I suggest you verify it yourself if I miscalculated it and if so please share your input rather than criticising an objective attempt to compare. Some investors see only the current share price without understanding mcap and the implication of the number of issued shares by the .company. Hence I thought I'd share the above. If you're too advanced or smart, then just ignore it.

Believe it or not, the above is just my opinion.

Best to all who believe in LBT.

Other related posts which might be of interest, with due credit to posters:

http://hotcopper.com.au/posts/19947968/single
http://hotcopper.com.au/posts/20015264/single
http://hotcopper.com.au/posts/20102336/single
http://hotcopper.com.au/posts/20108657/single
http://hotcopper.com.au/posts/20108858/single
http://hotcopper.com.au/posts/20113109/single